OKUR

OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, the Company is building a pipeline of tumor-agnostic candidates. It is developing OKI-219, a selective PI3KaH1047R inhibitor, as its lead program. It is engaged in targeting oncogenic PI3Ka and has multiple programs designed to enable targeting of this key oncogene. It is focused on delivering highly selective drug candidates that preserve wild-type PI3Ka while targeting the PI3Ka-mutated cancers, initially in advanced breast cancer. Its lead product candidate, OKI-219, is advancing in a phase I clinical trial. It also focuses on a development candidate targeting the most common PI3Ka mutations, such as H1047R, E545K, and E542K. Additionally, it is developing an allosteric inhibitor molecule.

Wall Street analysts forecast OKUR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OKUR is 25.50 USD with a low forecast of 17.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Onkure Therapeutics Inc revenue for the last quarter amounts to -15.50M USD, increased 232.35 % YoY.

Onkure Therapeutics Inc. EPS for the last quarter amounts to -13043000.00 USD, increased 471.81 % YoY.

Onkure Therapeutics Inc (OKUR) has 46 emplpoyees as of December 15 2025.

Today OKUR has the market capitalization of 41.59M USD.